April 2, 2026
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
March 17, 2026
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
February 25, 2026
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
February 24, 2026
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
February 18, 2026
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
February 4, 2026
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
January 29, 2026
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
January 8, 2026
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
January 5, 2026
Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy